Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Globe Newswire•05/10/2026•16:05 ET
0
Key Highlights
- ➤Eledon will present BESTOW patient-reported outcomes at ASN Kidney Week 2026
- ➤BESTOW evaluates tegoprubart versus tacrolimus for kidney-transplant rejection prevention
- ➤Presentation scheduled October 23, 2026, at 4:40 p.m. MDT
- ➤Tegoprubart is Eledon’s lead investigational anti-CD40L antibody
Expert Statements
Andrew B. Adams, M.D., Ph.D., Department of Surgery, University of Minnesota Medical School
“Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients”
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephrology Kidney Week 2026 Annual Meeting taking place in Denver, CO, from October 21-25, 2026. The oral presentation will highlight patient-reported outcomes from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation.
Title: Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprubart to Tacrolimus in Kidney Transplant Recipients
Get started
Create a free account to read the full story.